(134 days)
No
The summary does not mention AI, ML, deep learning, or any related terms in the device description, intended use, or performance studies. The modifications described are primarily hardware and software platform upgrades, along with the introduction of a protocol manager.
No
Explanation: The "Intended Use / Indications for Use" section explicitly states that the system is "indicated for use as a diagnostic device." While it can assist in therapy planning, its primary purpose is diagnosis, not therapy.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states, "This system is a Magnetic Resonance Medical Electrical Systems indicated for use as a diagnostic device." It further elaborates that the images, spectra, and measurements "provide information that may assist the diagnosis and therapy planning."
No
The device description explicitly mentions the introduction of a "new gradient system hardware with new gradient specifications," indicating the inclusion of physical hardware components beyond just software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the system is a "Magnetic Resonance Medical Electrical Systems indicated for use as a diagnostic device." It describes producing images, spectra, and measurements of physical parameters from the internal structure of the body. This is consistent with in-vivo imaging, not in-vitro testing of samples.
- Device Description: The description details a Magnetic Resonance (MR) system, which is an imaging modality used on living patients.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) or performing tests on these samples outside of the body, which are key characteristics of IVD devices.
The device is a Magnetic Resonance Imaging (MRI) system, which is a type of medical imaging device used for in-vivo diagnosis.
N/A
Intended Use / Indications for Use
This system is a Magnetic Resonance Medical Electrical Systems indicated for use as a diagnostic device. The system can produce cross-sectional images, spectroscopic images and/or spectra in any orientation of the internal structure of the head, body or extremities.
Magnetic Resonance images represent the spatial distribution of protons or other nuclei with spin. Image appearance is determined by many different physical properties of the tissue and the MR scan technique applied. The image acquisition process can be synchronized with the patient's breathing or cardiac cycle. The systems can use combinations of images to produce physical parameters, and related derived images.
Images, spectra, and measurements of physical parameters, when interpreted by a trained physician, provide information that may assist the diagnosis and therapy planning. The accuracy of determined physical parameters depends on system and scan parameters, and must be controlled and validated by the clinical user. The use of contrast agents for diagnostic imaging applications should be performed consistent with the approved labeling for the contrast agent.
In addition the Philips MR systems provide imaging capabilities, such as MR fluoroscopy, to guide and evaluate interventional and minimally invasive procedures in the head, body and extremities.
MR Interventional procedures, performed inside or adjacent to the Philips MR system, must be performed with MR Conditional or MR Safe instrumentation as selected and evaluated by the clinical user for use with the system configuration in the hospital. The appropriateness and use of information from a Philips MR system for a specific interventional procedure and specific MR system configuration must be validated by the clinical user.
Product codes
LNH, LNI
Device Description
The proposed Ingenia Elition S and Ingenia Elition X R5.4 with new gradient system/specifications are modifications of the 70 cm Ingenia 3.0T system, included in the legally marketed predicate device Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017). The systems and control software are substantially equivalent to the legally marketed predicate device Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017). Hereafter Ingenia Elition S and Ingenia Elition X R5.4 will be used to indicate the proposed device Ingenia Elition S and Ingenia Elition X R5.4 with new gradient system/specifications The proposed Ingenia Elition S and Ingenia Elition X R5.4 also includes minor software changes since the clearance of the legally marketed predicate device, Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017). The following modifications are covered compared to legally marketed predicate device: 1. Upgrade of SW platform to Windows 10 and PSC 6.1 (to be compatible with Windows 10); 2. PerformanceBridge Protocol Manager Release 1.0; 3. Introduction of new gradient system hardware with new qradient specifications: 4. Introduction of new product name and covers. The proposed Ingenia Elition S and Ingenia Elition X R5.4 are intended to be marketed with the following pulse sequences and coils that were previously cleared by FDA: 1. mDIXON K102344 2. SWIp K131241 3. mDIXON-Quant K133526 4. MRE K140666 5. mDIXON XD K143128 6. O-MAR K143253 7. MultiBand SENSE K143606 8. Ingenia Coils See Appendix 004
The proposed Ingenia Elition S and Ingenia Elition X R5.4 are based on the principle that certain atomic nuclei present in the human body will emit a weak relaxation signal when placed in a strong magnetic field and excited by a radio signal at the precession frequency. The emitted relaxation signals are analyzed by the system and a computed image reconstruction is displayed on a video screen.
The principal technological components (magnet, receive coils and patient support) of the proposed Ingenia Elition S and Ingenia Elition X R5.4 are identical to those used in the legally marketed predicate device, Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017), except for the transmit body coil and the gradient coil, which have been changed to adapt to the changed voltage levels of the gradient amplifier.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance
Anatomical Site
head, body or extremities
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained physician / hospital
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical verification and or validation tests have been performed with regards to the intended use, the technical claims, the requirement specifications and the risk management results. The verification and/or validation test results demonstrate that the proposed Ingenia Elition S and Ingenia Elition X R5.4:
• Complies with the aforementioned international and FDA recognized consensus standards and Device specific guidance document, entitled "Guidance for the Submission Of Premarket Notifications for Magnetic Resonance Diagnostic Devices - November 18, 2016"
• Meets the acceptance criteria and is adequate for its intended use.
The proposed Ingenia Elition S and Ingenia Elition X R5.4 did not require a clinical study since substantial equivalence to the legally marketed predicate device was proven with the verification/validation testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
K102344, K131241, K133526, K140666, K143128, K143253, K143606
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
March 20, 2018
Image /page/0/Picture/1 description: The image contains two logos. The logo on the left is the Department of Health & Human Services - USA logo. The logo on the right is the FDA U.S. Food & Drug Administration logo. The FDA logo is in blue and white.
Philips Medical Systems Nederland B.V. % Mr. Henrie Daniels Regulatory Affairs Specialist Veenpluis 4-6 5684 PC, Best THE NETHERLANDS
Re: K173451
Trade/Device Name: Ingenia Elition S and Ingenia Elition X Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: II Product Code: LNH, LNI Dated: February 7, 2018 Received: February 12, 2018
Dear Mr. Daniels:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael D. O'Hara For
Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
K173451
Device Name Ingenia Elition S and Ingenia Elition X
Indications for Use (Describe)
This system is a Magnetic Resonance Medical Electrical Systems indicated for use as a diagnostic device. The system can produce cross-sectional images, spectroscopic images and/or spectra in any orientation of the internal structure of the head, body or extremities.
Magnetic Resonance images represent the spatial distribution of protons or other nuclei with spin. Image appearance is determined by many different physical properties of the tissue and the MR scan technique applied. The image acquisition process can be synchronized with the patient's breathing or cardiac cycle. The systems can use combinations of images to produce physical parameters, and related derived images.
Images, spectra, and measurements of physical parameters, when interpreted by a trained physician, provide information that may assist the diagnosis and therapy planning. The accuracy of determined physical parameters depends on system and scan parameters, and must be controlled and validated by the clinical user. The use of contrast agents for diagnostic imaging applications should be performed consistent with the approved labeling for the contrast agent.
In addition the Philips MR systems provide imaging capabilities, such as MR fluoroscopy, to guide and evaluate interventional and minimally invasive procedures in the head, body and extremities.
MR Interventional procedures, performed inside or adjacent to the Philips MR system, must be performed with MR Conditional or MR Safe instrumentation as selected and evaluated by the clinical user for use with the system configuration in the hospital. The appropriateness and use of information from a Philips MR system for a specific interventional procedure and specific MR system configuration must be validated by the clinical user.
| Type of Use (Select one or both, as applicable) | Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the word "PHILIPS" in large, bold, blue letters. The letters are evenly spaced and fill most of the frame. The background is white, providing a strong contrast to the blue text.
Philips Medical Systems Nederland B.V. Magnetic Resonance Imaging Abbreviated 510(k)
Ingenia Elition S and Ingenia Elition X R5.4
Section 5
510(k) Summary
4
Image /page/4/Picture/0 description: The image shows the word "PHILIPS" in large, bold, blue letters. The font is sans-serif and the letters are evenly spaced. The background is white, which makes the blue letters stand out.
510(k) Summary of Safety and Effectiveness
This 510(k) summary of safety and effectiveness information is prepared in accordance with 21 CFR §807.92.
| Date Prepared: | October 20, 2017 |
|---|---|
| Manufacturer: | Philips Medical Systems Nederland B.V. |
| Veenpluis 4-6, 5684 PC, Best, The Netherlands | |
| Establishment Registration Number: 3003768277 | |
| Primary Contact Person: | Jan van de Kerkhof |
| Sr. Manager Regulatory Affairs | |
| Phone: +31 613300542 | |
| E-mail: jan.van.de.kerkhof@philips.com | |
| Secondary Contact Person | Henrie Daniels |
| Regulatory Affairs Specialist | |
| Telephone: +31 643837374 | |
| E-mail: henrie.daniels@philips.com | |
| Device Name: | Ingenia Elition S and Ingenia Elition X R5.4 |
| Classification: | Classification name: Magnetic Resonance Diagnostic Device (MRDD) |
| Classification Regulation: 21CFR 892.1000 | |
| Classification Panel: Radiology | |
| Device Class: Class II | |
| Primary Product Code: 90LNH | |
| 90LNI | |
| Primary Predicate Device: | Trade name: Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 |
| Manufacturer: Philips Medical Systems Nederland B.V. | |
| 510(k) Clearance: K163116 | |
| Classification Regulation: 21CFR 892.1000 | |
| Classification name: Magnetic Resonance Diagnostic Device (MRDD) | |
| Classification Panel: Radiology | |
| Device class: Class II | |
| Product Code: 90LNH | |
| 90LNI |
5
Image /page/5/Picture/0 description: The image shows the word "PHILIPS" in large, bold, blue letters. The letters are evenly spaced and fill the majority of the frame. The background is plain white, which makes the blue letters stand out.
The proposed Ingenia Elition S and Ingenia Elition X R5.4 with Device Description: new gradient system/specifications are modifications of the 70 cm Ingenia 3.0T system, included in the legally marketed predicate device Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017). The systems and control software are substantially equivalent to the legally marketed predicate device Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017). Hereafter Ingenia Elition S and Ingenia Elition X R5.4 will be used to indicate the proposed device Ingenia Elition S and Ingenia Elition X R5.4 with new gradient system/specifications The proposed Ingenia Elition S and Ingenia Elition X R5.4 also includes minor software changes since the clearance of the legally marketed predicate device, Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116, 01/06/2017). The following modifications are covered compared to legally marketed predicate device: 1. Upgrade of SW platform to Windows 10 and PSC 6.1 (to be compatible with Windows 10); 2. PerformanceBridge Protocol Manager Release 1.0; 3. Introduction of new gradient system hardware with new qradient specifications: 4. Introduction of new product name and covers. The proposed Ingenia Elition S and Ingenia Elition X R5.4 are intended to be marketed with the following pulse sequences and coils that were previously cleared by FDA: 1. mDIXON K102344 2. SWIp K131241 3. mDIXON-Quant K133526 4. MRE K140666 5. mDIXON XD K143128 6. O-MAR K143253 7. MultiBand SENSE K143606 8. Ingenia Coils See Appendix 004
6
Image /page/6/Picture/0 description: The image shows the word "PHILIPS" in large, bold, blue letters. The letters are evenly spaced and fill most of the frame. The background is white, providing a strong contrast to the blue text.
| Indications for Use: | This system is a Magnetic Resonance Medical Electrical Systems |
|---|---|
| indicated for use as a diagnostic device. The system can produce | |
| cross-sectional images, spectroscopic images and/or spectra in | |
| any orientation of the internal structure of the head, body or | |
| extremities. | |
| Magnetic Resonance images represent the spatial distribution of | |
| protons or other nuclei with spin. Image appearance is determined | |
| by many different physical properties of the tissue and the | |
| anatomy, and the MR scan technique applied. The image | |
| acquisition process can be synchronized with the patient's | |
| breathing or cardiac cycle. The systems can use combinations of | |
| images to produce physical parameters, and related derived | |
| images. | |
| Images, spectra, and measurements of physical parameters, | |
| when interpreted by a trained physician, provide information that | |
| may assist the diagnosis and therapy planning. The accuracy of | |
| determined physical parameters depends on system and scan | |
| parameters, and must be controlled and validated by the clinical | |
| user. The use of contrast agents for diagnostic imaging | |
| applications should be performed consistent with the approved | |
| labeling for the contrast agent. | |
| In addition the Philips MR systems provide imaging capabilities, | |
| such as MR fluoroscopy, to guide and evaluate interventional and | |
| minimally invasive procedures in the head, body and extremities. | |
| MR Interventional procedures, performed inside or adjacent to the | |
| Philips MR system, must be performed with MR Conditional or MR | |
| Safe instrumentation as selected and evaluated by the clinical | |
| user for use with the specific MR system configuration in the | |
| hospital. The appropriateness and use of information from a | |
| Philips MR system for a specific interventional procedure and | |
| specific MR system configuration must be validated by the clinical | |
| user. |
7
Image /page/7/Picture/0 description: The image shows the word "PHILIPS" in a bold, sans-serif font. The letters are all capitalized and colored in a bright blue. The background is white, providing a strong contrast that makes the word stand out.
| Design Features/
Fundamental Scientific
Technology: | The proposed Ingenia Elition S and Ingenia Elition X R5.4 are
based on the principle that certain atomic nuclei present in the
human body will emit a weak relaxation signal when placed in a
strong magnetic field and excited by a radio signal at the
precession frequency. The emitted relaxation signals are analyzed
by the system and a computed image reconstruction is displayed
on a video screen.
The principal technological components (magnet, receive coils
and patient support) of the proposed Ingenia Elition S and
Ingenia Elition X R5.4 are identical to those used in the legally
marketed predicate device, Ingenia 1.5T, Ingenia 1.5T S and
Ingenia 3.0T R5.3 (K163116, 01/06/2017), except for the transmit
body coil and the gradient coil, which have been changed to adapt
to the changed voltage levels of the gradient amplifier.
Based on the information provided above, the proposed Ingenia
Elition S and Ingenia Elition X R5.4 does not raise different
questions of safety and effectiveness compared to the legally
marketed predicate device Ingenia 1.5T, Ingenia 1.5T S and
Ingenia 3.0T R5.3 (K163116, 01/06/2017). |
| ----------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
|---|
8
Image /page/8/Picture/0 description: The image shows the word "PHILIPS" in large, bold, blue letters. The letters are evenly spaced and fill most of the frame. The background is white, providing a strong contrast to the blue letters.
| Summary of Non-
Clinical Performance
Data: | The proposed Ingenia Elition S and Ingenia Elition X R5.4
comply with the following international and FDA-recognized
consensus standards: |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | • IEC60601-1 Edition 3 |
| | • IEC60601-1-2 Edition 3 |
| | • IEC60601-1-6 Edition 3 |
| | • IEC62366 Edition 1 |
| | • IEC60601-1-8 Edition 2 |
| | • IEC60601-2-33 Edition 3 |
| | • IEC 62304 Edition 1 |
| | • NEMA MS-1 2008 |
| | • NEMA MS-4 2010 |
| | • NEMA MS-8 2008 |
| | • NEMA PS 3.1-PS 3.20 |
| | • ISO 14971 Edition 2 |
| | • Device specific guidance document, entitled "Guidance for the
Submission Of Premarket Notifications for Magnetic Resonance
Diagnostic Devices – November 18, 2016" |
| | • Guidance for Industry and FDA Staff - Guidance for the Content
of Premarket Submissions for Software Contained in Medical
Devices (issued May 11, 2005) |
| | • Guidance for Industry and FDA Staff - Applying Human Factors
and Usability Engineering to Medical Devices 9 issued February
3, 2016) |
| | • Guidance for Industry and FDA Staff - Content of Premarket
Submissions for Management of Cybersecurity in Medical
Devices issued October 2, 2014 |
| | • Guidance for Industry and FDA Staff – Use of International
Standard ISO 10993-1, "Biological evaluation of medical
devices – Part 1: Evaluation and testing within a risk
management process" (issued June 16, 2016) |
| | • Guidance for Industry and FDA Staff – Information to Support a
Claim of Electromagnetic Compatibility (EMC) of Electrically-
Powered Medical Devices (issued July 11, 2016) |
| | Non-Clinical verification and or validation tests have been
performed with regards to the intended use, the technical claims,
the requirement specifications and the risk management results. |
| | The verification and/or validation test results demonstrate that the |
9
Image /page/9/Picture/0 description: The image shows the word "PHILIPS" in large, bold, blue letters. The letters are evenly spaced and fill most of the frame. The background is white, providing a strong contrast to the blue letters.
| | • Complies with the aforementioned international and FDA
recognized consensus standards and Device specific
guidance document, entitled "Guidance for the Submission Of
Premarket Notifications for Magnetic Resonance Diagnostic
Devices - November 18, 2016"
• Meets the acceptance criteria and is adequate for its intended
use. |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Therefore, the proposed Ingenia Elition S and Ingenia Elition X
R5.4 are substantially equivalent to the legally marketed predicate
device Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3
(K163116, 01/06/2017) in terms of safety and effectiveness. |
| Summary of Clinical
Data: | The proposed Ingenia Elition S and Ingenia Elition X R5.4 did
not require a clinical study since substantial equivalence to the
legally marketed predicate device was proven with the
verification/validation testing. |
| Substantial
Equivalence: | The proposed Ingenia Elition S and Ingenia Elition X R5.4 and
the legally marketed predicate device Ingenia 1.5T, Ingenia 1.5T
S and Ingenia 3.0T R5.3 (K163116, 01/06/2017) have the same
indications for use with respect to the following:
• Providing cross-sectional images based on the magnetic
resonance phenomenon
• Interpretation of the images is the responsibility of trained
physicians
• Images can be used for interventional and treatment planning
purposes
The proposed Ingenia Elition S and Ingenia Elition X R5.4 are
substantially equivalent to the legally marketed predicate device
Ingenia 1.5T, Ingenia 1.5T S and Ingenia 3.0T R5.3 (K163116,
01/06/2017) in terms of design features, fundamental scientific |
| | technology, indications for use, and safety and effectiveness.
Additionally, substantial equivalence was demonstrated with non-
clinical performance (verification and validation) tests, which
complied with the requirements specified in the international and
FDA-recognized consensus standards and device-specific
guidance. |
| Conclusion: | The results of these tests demonstrate that the proposed Ingenia
Elition S and Ingenia Elition X R5.4 meet the acceptance criteria
and is adequate for its intended use. |